WIXOM, Mich.— Rockwell Medical unveiled on Oct. 27 a new corporate identity, which includes a new logo, company name and Web site.
Rockwell Medical, formerly known as Rockwell Medical Technologies Inc., is a biopharmaceutical company that offers products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia.
"Our new name, Rockwell Medical, more accurately reflects the strategic direction and corporate identity of our company,” Robert L. Chioini, chairman and CEO, said in a statement. "Our new Web site will enable us to provide greater content and accessibility to our customers as we continue to position the organization as a leading biopharmaceutical company building a pipeline of drug therapies in the renal and anemia space."
Rockwell's new Web site at www.rockwellmed.com provides information on kidney disease and has been streamlined to meet the needs of its customers, while focusing on its biopharmaceutical product development and scientific innovation in the renal industry.
As part of the Web site, Rockwell has developed a video to illustrate the mechanism of action and potential competitive advantages of Soluble Ferric Pyrophosphate (SFP), the company’s proprietary, investigational iron maintenance therapy currently in a U.S. Phase 2b clinical study. To view the video, visit the Rockwell homepage and click on SFP Mode of Action under Resources.